The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed medical journals, clinical publications, and authoritative respiratory health organizations. Key sources included the US Food & Drug Administration (FDA) Centre for Drug Evaluation and Research (CDER), European Medicines Agency (EMA) Human Medicines Division, World Health Organization (WHO) Global Health Observatory, Centers for Disease Control and Prevention (CDC) National Center for Health Statistics, National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (NHLBI), National Center for Biotechnology Information (NCBI/PubMed), European Centre for Disease Prevention and Control (ECDC), American Lung Association (ALA) Epidemiology and Statistics Unit, European Respiratory Society (ERS) White Papers, American Thoracic Society (ATS) Clinical Guidelines, Global Initiative for Asthma (GINA) Reports, Global Initiative for Chronic Obstructive Lung Disease (GOLD) Strategy Documents, International Society for Aerosols in Medicine (ISAM) Publications, IQVIA National Prescription Audit, IMS Health MIDAS Database, and national health ministry reports from key markets (NHS UK, CMS US, NHI Japan).
These sources were employed to gather prescription statistics, regulatory approval data for MDI and DPI devices, clinical efficacy studies for bronchodilators and corticosteroids, asthma/COPD prevalence trends, reimbursement policies, and competitive landscape analysis for manually operated versus digitally operated inhaler technologies.